|
Sinoway Industrial Co.Ltd.
|
Product name
|
Ritonavir
|
CAS No.
|
155213-67-5
|
Molecular Formula
|
C37H48N6O5S2
|
Molecular Weight
|
720.96
|
Quality Standard
|
99% up, USP42, Medicine Grade
|
Appearance
|
White powder
|
Items
|
Specifications
|
Results
|
Appearance
|
White to off-white powder
|
White powder
|
Solubility
|
Freely solution in methanol and in ethanol,
soluble in 2-propanol
|
Conforms
|
Identification
|
HPLC: the retention time of the test sample
corresponds to that
of the reference standard
IR: the infrared absorption spectrum of
the test sample is concordant
with the spectrum of reference standard
|
Conforms
Conforms
|
Water content by KF
|
NMT 0.5%
|
0.06%
|
Specific optical rotation
|
+7.0°~+10.5°(c=2 in MeOH)
|
+10.21°
|
Residue on ignition
|
NMT 0.2%
|
0.10%
|
Heavy metals
|
NMT 20 ppm
|
Conforms
|
Sulphated ash
|
NMT 0.105
|
0.03%
|
Organic volatile impurities
|
Ethylacetate: NMT 0.5%
Heptane: NMT 0.5%
Tetrahydrofuran: NMT 0.072%
|
0.40%
0.16%
ND
|
Related substances (by HPLC, area%)
|
Impurity E (RRT=0.36):NMT 0.3%
ImpurityO(RRT=1.11):NMT 0.3%
Impurity T (RRT=2.87):NMT 0.2%
Any other individual impurity: NMT 0.1%
Total impourities: NMT1.0%
|
0.08%
ND
ND
Conforms
0.16%
|
Assay (by HPLC)
|
98.0%~102.0%
|
99.0%
|
Function of Ritonavir
What is Ritonavir ?
Ritonavir is a Whtie powder, It's CAS No. is 155213-67-5, It's molecular formula is C37H48N6O5S2.
Ritonavir, with trade name Norvir (AbbVie, Inc.), is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS.
Function of Ritonavir
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV.
It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulation and as capsules.
Application of Ritonavir
1. Ritonavir is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS.
2. Ritonavir is a Pharmaceutical raw materials.
3. Although it was initially developed as an independent agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. |
Send Inquiry
|
Pharma Sources Insight June 2024: Globalization on the Go
